Navigation Links
Clinical Study Shows Regenecare Relieves Pain and Itching of Skin,Rashes Caused by Widely Used Cancer Drugs

IRVING, Texas--(BUSINESS WIRE)--Jul 11, 2007 - The Journal of the American Society of Clinical Oncology has published the early results of a clinical study conducted by Dr. Siu-Fun Wong, and her colleagues, which concluded that the topical gel, Regenecare(R), caused a statistically significant reduction in the pain and itching of a rash that results from the use of anti-cancer drugs known as EGFR inhibitors. This ongoing supportive care trial is listed on the National Cancer Institute Clinical Trials website (www.cancer.gov).

Paul Miller, President of MPM Medical, stated, "EGFR inhibitors form a group of drugs, sold by several pharmaceutical companies, which are effective in the treatment of cancer. However, after a few weeks of use, an acne-like rash often appears on the face, neck, back, hands, and/or legs resulting in severe pain and itching for the patient. We know of no other evidence-based topical applications reported in the scientific literature shown to help manage rash symptoms caused by EGFR drugs."

Regenecare(R) is a proprietary product of MPM Medical, Inc., a wholly owned subsidiary of RBC Life Sciences, Inc. (OTCBB:RBCL).

MPM Medical develops and markets a line of prescription and nonprescription products for wound management, through medical-surgical dealers, to nursing homes, hospitals, and cancer clinics.

The statements above, other than statements of historical facts, may be forward-looking. Actual events will be dependent upon a number of factors and risks including but not limited to changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.

Contact

RBC Life Sciences, Inc.
Steve Brown, CFO, 972-893 4000
steveb@rbcls.com
www.mpmmedicalinc.com


'"/>




Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
3. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... and PUNE, India , January 18, ... Allied Market Research, titled, "Breast Imaging Technologies Market by Type: ... global breast imaging technologies market size was valued at $2,544 ... by 2022, growing at a CAGR of 8.4% from 2016 ... Europe together accounted for over three-fourths market ...
(Date:1/18/2017)... , Jan. 18, 2017   Regenicin, Inc. ... biotechnology company specializing in the development and commercialization of ... tissues and organs, recently reported the Company,s operating results ... 2017. As the Company described in its ... a year of substantial accomplishments. The Company,s contract laboratory ...
(Date:1/18/2017)... , Suiza, 18 de enero de 2017  Hoy, ... lanzaron Access Accelerated, una iniciativa global para avanzar el ... y atención en países de renta baja y baja-media ... alcanzado un punto de crisis, particularmente en países de ... 80 por ciento de las muertes relacionadas con NCD. ...
Breaking Medicine Technology:
(Date:1/19/2017)... NJ (PRWEB) , ... January 19, 2017 , ... ... locally owned insurance agency which serves Lawrenceville, New Jersey and the surrounding area, ... , Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease ...
(Date:1/19/2017)... CA (PRWEB) , ... January 18, 2017 , ... The ... while driving during a rain storm by slowing down and increasing the space between ... Fox 40. Los Angeles based car accident attorney Raymond R. Hassanlou notes that, rain ...
(Date:1/19/2017)... Viejo, California (PRWEB) , ... January 19, 2017 ... ... animating paragraph styled text designs that will simplify the editing process for all ... , ProParagraph Basics is a package of 30 simplistically styled self-animating paragraphs designed ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... A recent ... opened a global discussion about the benefits of fidgeting to relieve stress and anxiety. ... Jym Daniel. Their Think Ink Pen had just completed a successful Kickstarter campaign ...
(Date:1/18/2017)... ANN ARBOR, Mich. USA; SAN JOSE, Calif, USA; and SHANGHAI, ... ... (PRWEB) January 18, 2017 -- Global public ... pitcher to reduce arsenic V (pentavalent arsenic) to NSF/ANSI 53: ... Standard for drinking water treatment units. This certification verifies that ...
Breaking Medicine News(10 mins):